ALK-Abelló A/S (ALK-B) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.112x

Based on the latest financial reports, ALK-Abelló A/S (ALK-B) has a cash flow conversion efficiency ratio of 0.112x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr722.00 Million ≈ $112.96 Million USD) by net assets (Dkr6.45 Billion ≈ $1.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

ALK-Abelló A/S - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how ALK-Abelló A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALK-B total debt and obligations for a breakdown of total debt and financial obligations.

ALK-Abelló A/S Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ALK-Abelló A/S ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Inpost SA
AS:INPST
0.237x
The Federal Bank Limited
NSE:FEDERALBNK
0.083x
Planet Labs PBC
NYSE:PL
0.082x
BYD Electronic (International) Company Limited
F:4BY
0.036x
Commercial Metals Company
NYSE:CMC
0.047x
Thai Beverage Public Company Limited
F:T6W
0.035x
Shenzhen Capchem Tech
SHE:300037
0.033x
UGI Corporation
NYSE:UGI
0.013x

Annual Cash Flow Conversion Efficiency for ALK-Abelló A/S (2005–2025)

The table below shows the annual cash flow conversion efficiency of ALK-Abelló A/S from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see ALK-Abelló A/S stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Dkr6.45 Billion
≈ $1.01 Billion
Dkr1.82 Billion
≈ $284.28 Million
0.282x +24.88%
2024-12-31 Dkr5.37 Billion
≈ $840.64 Million
Dkr1.21 Billion
≈ $189.78 Million
0.226x +50.52%
2023-12-31 Dkr4.45 Billion
≈ $695.77 Million
Dkr667.00 Million
≈ $104.36 Million
0.150x +43.79%
2022-12-31 Dkr3.99 Billion
≈ $623.95 Million
Dkr416.00 Million
≈ $65.09 Million
0.104x -22.43%
2021-12-31 Dkr3.48 Billion
≈ $544.47 Million
Dkr468.00 Million
≈ $73.22 Million
0.134x +40.87%
2020-12-31 Dkr3.15 Billion
≈ $493.31 Million
Dkr301.00 Million
≈ $47.09 Million
0.095x +129.69%
2019-12-31 Dkr3.18 Billion
≈ $496.91 Million
Dkr132.00 Million
≈ $20.65 Million
0.042x +239.08%
2018-12-31 Dkr3.18 Billion
≈ $497.38 Million
Dkr-95.00 Million
≈ $-14.86 Million
-0.030x +74.60%
2017-12-31 Dkr3.29 Billion
≈ $514.74 Million
Dkr-387.00 Million
≈ $-60.55 Million
-0.118x -183.50%
2016-12-31 Dkr2.88 Billion
≈ $449.81 Million
Dkr405.00 Million
≈ $63.37 Million
0.141x +107.61%
2015-12-31 Dkr2.70 Billion
≈ $421.97 Million
Dkr183.00 Million
≈ $28.63 Million
0.068x -50.09%
2014-12-31 Dkr2.35 Billion
≈ $368.30 Million
Dkr320.00 Million
≈ $50.07 Million
0.136x +109.40%
2013-12-31 Dkr2.25 Billion
≈ $351.87 Million
Dkr146.00 Million
≈ $22.84 Million
0.065x +62.94%
2012-12-31 Dkr2.28 Billion
≈ $357.35 Million
Dkr91.00 Million
≈ $14.24 Million
0.040x -79.97%
2011-12-31 Dkr2.17 Billion
≈ $339.04 Million
Dkr431.00 Million
≈ $67.43 Million
0.199x +46.48%
2010-12-31 Dkr2.02 Billion
≈ $315.73 Million
Dkr274.00 Million
≈ $42.87 Million
0.136x +0.68%
2009-12-31 Dkr1.93 Billion
≈ $301.65 Million
Dkr260.00 Million
≈ $40.68 Million
0.135x +32.86%
2008-12-31 Dkr1.86 Billion
≈ $291.32 Million
Dkr189.00 Million
≈ $29.57 Million
0.102x -40.78%
2007-12-31 Dkr2.11 Billion
≈ $330.44 Million
Dkr362.00 Million
≈ $56.64 Million
0.171x +498.19%
2006-12-31 Dkr2.09 Billion
≈ $327.62 Million
Dkr60.00 Million
≈ $9.39 Million
0.029x +1.65%
2005-12-31 Dkr6.21 Billion
≈ $971.29 Million
Dkr175.00 Million
≈ $27.38 Million
0.028x --

About ALK-Abelló A/S

CO:ALK-B Denmark Biotechnology
Market Cap
$7.62 Billion
Dkr48.72 Billion DKK
Market Cap Rank
#2704 Global
#15 in Denmark
Share Price
Dkr242.00
Change (1 day)
+1.51%
52-Week Range
Dkr159.00 - Dkr242.00
All Time High
Dkr242.00
About

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more